# Catherine Harwood

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/catherine-harwood/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,486 |
| Field | Nonmelanoma Skin Cancer Studies |
| h-index | 73 |
| i10-index | 178 |
| Last Known Institution | Queen Mary University of London |
| OpenAlex ID | https://openalex.org/A5044662843 |
| ORCID iD | 0000-0002-1375-0965 |
| Works | 406 |

## Researcher papers

Showing 12 of 14.

- [Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer](https://scholariq.org/papers/role-of-a-p53-polymorphism-in-the-development-of-human-papilloma-virus/)
- [Azathioprine and UVA Light Generate Mutagenic Oxidative DNA Damage](https://scholariq.org/papers/azathioprine-and-uva-light-generate-mutagenic-oxidative-dna-damage/)
- [Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines](https://scholariq.org/papers/diagnosis-and-treatment-of-basal-cell-carcinoma-european-consensus-based/)
- [Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial](https://scholariq.org/papers/azithromycin-in-patients-admitted-to-hospital-with-covid-19-recovery-a/)
- [Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial](https://scholariq.org/papers/convalescent-plasma-in-patients-admitted-to-hospital-with-covid-19-recovery-a/)
- [A common polymorphism acts as an intragenic modifier of mutant p53 behaviour](https://scholariq.org/papers/a-common-polymorphism-acts-as-an-intragenic-modifier-of-mutant-p53-behaviour/)
- [Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals](https://scholariq.org/papers/human-papillomavirus-infection-and-non-melanoma-skin-cancer-in-immunosuppressed/)
- [Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial](https://scholariq.org/papers/casirivimab-and-imdevimab-in-patients-admitted-to-hospital-with-covid-19/)
- [NOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis](https://scholariq.org/papers/notch1-mutations-occur-early-during-cutaneous-squamous-cell-carcinogenesis/)
- [Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis](https://scholariq.org/papers/baricitinib-in-patients-admitted-to-hospital-with-covid-19-recovery-a-randomised/)
- [European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment](https://scholariq.org/papers/european-interdisciplinary-guideline-on-invasive-squamous-cell-carcinoma-of-the/)
- [ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease](https://scholariq.org/papers/ecco-guidelines-on-extraintestinal-manifestations-in-inflammatory-bowel-disease/)

## Researcher topics

- [Nonmelanoma Skin Cancer Studies](https://scholariq.org/topics/nonmelanoma-skin-cancer-studies/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Cancer and Skin Lesions](https://scholariq.org/topics/cancer-and-skin-lesions/)
- [Cutaneous lymphoproliferative disorders research](https://scholariq.org/topics/cutaneous-lymphoproliferative-disorders-research/)
- [Cervical Cancer and HPV Research](https://scholariq.org/topics/cervical-cancer-and-hpv-research/)

## Researcher university

- [Queen Mary University of London](https://scholariq.org/institutions/queen-mary-university-of-london/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.